LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma-Reference-Cited by-同舟云学术

LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma

Published:2024-05-07 Issue: Volume: Page:1-13
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Sun Jong-Mu¹,Adenis Antoine²,C Enzinger Peter³,Shah Manish A⁴^ORCID,Kato Ken⁵^ORCID,Bennouna Jaafar⁶,Doi Toshihiko⁷,Hawk Natalyn Nicole⁸,Yu Li⁹,Shah Sukrut⁹,Bhagia Pooja⁹,Shen Lin¹⁰

Affiliation:

1. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

2. Institut du Cancer de Montpellier & IRCM, Université Montpellier, Montpellier, France

3. Dana-Farber Cancer Institute, Boston, MA, USA

4. Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA

5. National Cancer Center Hospital, Tokyo, Japan

6. University Hospital of Nantes, Nantes, France

7. National Cancer Center Hospital East, Kashiwa, Japan

8. Eisai Inc., Nutley, NJ, USA

9. Merck & Co., Inc., Rahway, NJ, USA

10. Peking University Cancer Hospital & Institute, Beijing, China

Funder

Eisai Inc., Nutley, NJ, USA

Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.2217/fon-2022-1148

Reference58 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries

3. Cancer Statistics, 2021

4. Esophageal Cancer: An Updated Surveillance Epidemiology and End Results Database Analysis

5. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up